Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 143

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 143
---
 for the year of the disposition. In these circumstances, the tax will generally
be determined by allocating such distributions or gain ratably over the U. S. Holder’s holding period for the ADSs. The amount allocated
to the current taxable year and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income (rather
than capital gain) earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest applicable
marginal rates for the year and an interest charge at the rate applicable to underpayments of tax will also be imposed on the amount of
taxes allocated to such other taxable years.

An indirect shareholder may
be taxed on a distribution paid to the direct owner of a PFIC and on a disposition of the share indirectly owned. Indirect shareholders
are strongly urged to consult their tax advisors regarding the application of these rules.

If we are a PFIC and subsequently
cease to be a PFIC in a future year, a U. S. Holder may avoid the continued application of the tax treatment described above by electing
to be treated as if it sold its ADSs on the last day of the last taxable year in which we were a PFIC. Any gain would generally be recognized
and subject to tax under the excess distribution regime described above. Loss would not be recognized. A U. S. Holder’s basis in
its ADSs would be increased by the amount of gain, if any, recognized on the deemed sale. A U. S. Holder would be required to treat its
holding period for its ADSs as beginning on the day following the last day of the last taxable year in which we were a PFIC.

If the ADSs are
considered “marketable stock” and if a U. S. Holder properly elects to “mark-to-market” its ADSs in a timely
fashion, the U. S. Holder would not be subject to tax under the excess distribution regime described above. Instead, the U. S. Holder
would generally include in income any excess of the fair market value of the ADSs at the close of each tax year over the adjusted
tax basis of the ADSs. If the fair market value of the ADSs had depreciated below the adjusted basis at the close of the tax year,
the U. S. Holder would be entitled to deduct the excess of the adjusted basis of the ADSs over their fair market value at that time.
However